Last Update 21 Feb 26

Fair value Decreased 2.12%

RCUS: Future Upside Will Be Driven By Renal Cancer Data Milestones

Narrative Update: Arcus Biosciences

The analyst price target for Arcus Biosciences has been adjusted slightly lower to $32.30 from $33.00, as analysts weigh recent upgrades and downgrades that highlight both the potential of casdatifan in renal cell carcinoma and a more balanced risk and reward profile at current levels.

Analyst Commentary

Recent Street research on Arcus Biosciences reflects a mix of optimism around casdatifan and caution around timing, risk and current valuation, which together help explain the modest trim in the overall price target.

Bullish Takeaways

Bullish analysts highlight casdatifan as a key value driver, describing it as a potent and selective HIF-2alpha inhibitor for advanced clear cell renal cell carcinoma, with clear focus on a defined patient population in the US and EU.
The estimated total addressable market of about 17,400 patients and around US$1.7b in risk adjusted peak sales for casdatifan is a central pillar of the constructive view on Arcus's long term revenue potential.
Phase 1 ARC-20 data in second line settings, with reported overall response ratios of 31% for monotherapy and 46% for the combination regimen, are seen by bullish analysts as clinically supportive for the program and a key underpin for their valuation work.
Bullish analysts also point to five emerging inflammatory and other high risk oncology programs, including NSCLC and PDAC, as longer term optionality that is not fully reflected in some current models.

Bearish Takeaways

Bearish analysts see a more balanced risk and reward profile at current share levels, which leads them to temper expectations despite the clinical and commercial potential of casdatifan.
Some caution centers on the development timeline, with comments that much of the investor focus will stay on casdatifan while only incremental updates are expected in 2026, which could limit near term catalysts.
Price targets reduced to around US$20 from higher levels reflect concern that execution, data flow and risk around key programs may already be reflected in the share price.
Overall, more cautious views emphasize that while casdatifan remains central to the story, concentration in a single lead asset and reliance on future clinical milestones increase execution risk for Arcus at this stage.

What's in the News

Arcus outlined 2026 priorities for casdatifan in clear cell renal cell carcinoma, including at least three planned ARC-20 data readouts across late line, IO experienced and early line metastatic settings, with combinations such as casdatifan plus cabozantinib and casdatifan plus zimberelimab. (Key Developments)
The company highlighted a "fast to market" approach in ccRCC, linking mid 2026 ARC-20 combination data with the ongoing Phase 3 PEAK-1 study, and flagged the potential start of a Phase 3 registrational trial in an early or first line ccRCC setting in late 2026. (Key Developments)
Arcus and partner Gilead decided to discontinue the Phase 3 STAR-221 study and the Phase 2 EDGE-Gastric study in gastric and esophageal cancers after an interim analysis showed the domvanalimab based regimen did not improve overall survival versus nivolumab plus chemotherapy, while safety profiles were similar. (Key Developments)
Following the STAR-221 outcome, Arcus indicated that research and development resources will concentrate on casdatifan and oral inflammation and immunology programs, with multiple casdatifan data updates and go or no go decisions planned in 2026. (Key Developments)
The company also pointed to quemliclustat in first line pancreatic cancer, where the Phase 3 PRISM-1 study has completed enrollment, with results expected in 2027, and to planned clinical entry for MRGPRX2 and TNF small molecule programs in I&I indications beginning in 2026. (Key Developments)

Valuation Changes

Fair Value: trimmed slightly to $32.30 from $33.00, reflecting a modest reset in the implied upside.
Discount Rate: nudged higher to about 7.15% from 7.14%, signaling a small increase in the required return used in the model.
Revenue Growth: revised from about 0.93% growth to a 2.41% decline, pointing to a more conservative view on future revenue trends.
Net Profit Margin: reduced to about 15.70% from 16.96%, indicating a slightly lower assumed level of future earnings efficiency.
Future P/E: raised to about 129.3x from 110.6x, implying a higher multiple being applied to projected earnings despite the lower fair value.

1 view

Key Takeaways

Arcus Biosciences is focusing on casdatifan's late-stage development, promising significant differentiation and competitive advantage in the RCC market.
Strong financial partnerships and a long cash runway ensure sustained R&D investment and potential earnings growth through strategic planning.
Regulatory uncertainties, adverse event risks, competition, and strategic shifts may challenge Arcus Biosciences' financial outlook and market positioning.

Catalysts

About Arcus Biosciences

A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.What are the underlying business or industry changes driving this perspective?

Arcus Biosciences is prioritizing the launch of its late-stage development program for the HIF-2 alpha inhibitor, casdatifan, which has shown significant efficacy differentiation relative to existing market competitors. This could enhance future revenue through competitive advantage in the RCC market.
The company plans to present further data throughout 2025 from ongoing studies, which are expected to demonstrate favorable outcomes such as improved overall response rate (ORR) and progression-free survival (PFS). These outcomes could significantly impact future revenue growth as the positive data could drive market share gains.
Arcus Biosciences is advancing several Phase 3 trials, including the PEAK-1 study for casdatifan in combination with cabozantinib, targeting a substantial patient population that represents a multi-billion dollar market opportunity. Successful trials would bolster projected revenue streams.
The strategy to target first-line gastric cancer with the STAR-221 study, and lung cancer with STAR-121 and PACIFIC-8 trials, addresses large market opportunities with potential first-mover advantages. Positive results could lead to increased earnings through product differentiation and expanded market access.
Arcus has secured strong financial partnerships and maintains a cash runway supported into mid-2027, enabling sustained R&D investment and operational activities. This financial stability supports potential earnings growth through long-term strategic planning and execution.

Arcus Biosciences Earnings and Revenue Growth

Arcus Biosciences Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Arcus Biosciences's revenue will grow by 7.7% annually over the next 3 years.
Analysts are not forecasting that Arcus Biosciences will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Arcus Biosciences's profit margin will increase from -113.7% to the average US Biotechs industry of 16.1% in 3 years.
If Arcus Biosciences's profit margin were to converge on the industry average, you could expect earnings to reach $52.5 million (and earnings per share of $0.4) by about September 2028, up from $-298.0 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 85.5x on those 2028 earnings, up from -4.2x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.81%, as per the Simply Wall St company report.

Arcus Biosciences Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

There is ongoing uncertainty and risks surrounding the regulatory approval process for new therapies, such as dom-zim and casdatifan, which could delay potential revenue streams and impact financial projections in the coming years.
Higher rates of immune-related adverse events reported for Fc-enabled TIGIT antibodies might limit market acceptance and patient uptake for similar treatments, potentially affecting earnings.
Competition from other pharmaceutical companies, particularly Merck's advancements with belzutifan combinations, could pressure Arcus's market share and impact revenue growth.
The reliance on cash runway projections assumes consistent funding scenarios and clinical milestones that may not materialize as expected, leading to financial strain and impacting net margins.
The strategic decision to terminate the ARC-10 study and focus resources on STAR-121 may pose execution risks if the new focus areas don't achieve clinical success, thereby affecting future revenue streams.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $28.364 for Arcus Biosciences based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $47.0, and the most bearish reporting a price target of just $12.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $327.1 million, earnings will come to $52.5 million, and it would be trading on a PE ratio of 85.5x, assuming you use a discount rate of 6.8%.
Given the current share price of $11.64, the analyst price target of $28.36 is 59.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Arcus Biosciences?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analyst Sentiment Improves on Arcus Biosciences as Price Targets Rise with Strong Trial Data